>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Anti-Rituximab Antibodies on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Rituximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized rituximab at 5 µg/mL, add increasing concentrations of Anti-Rituximab Antibodies (Cat. No. RIB-Y35, 10% human serum) and then add biotinylated rituximab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 20 ng/mL.
Demonstration of the specificity of Anti-Rituximab Antibodies (Cat. No. RIB-Y35) to the rituximab.
Detection of rituximab by anti-idiotypic capture ELISA in serum. Immobilized Anti-Rituximab Antibodies (Cat. No. RIB-Y35) at 0.5 μg/mL (100 μL/well), add increasing concentrations of rituximab (0.1% human serum). Detection was performed using goat Anti-Human IgG with a sensitivity of 0.156 μg/mL.
Anti-Rituximab Antibodies (mouse IgG1, Cat. No. RIB-Y35) captured on CM5 chip via anti-mouse antibodies surface, can bind Human rituximab with an affinity constant of 0.03 nM.
FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibodies (Cat. No. RIB-Y35). The concentration of rituximab used is 10 ng/mL. The IC50 is 0.013 μg/mL (Routinely tested).
2e5 Anti-CD20 (Rituximab)-CAR 293 cells were first stained with Anti-Rituximab Antibodies (mouse IgG1, Cat. No. RIB-Y35) and followed by incubation with PE-labeled Anti-Mouse IgG1 antibody. PE-labeled Anti-Mouse IgG1 antibody was used as a negative control (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.